BVA-200 vs BVA-100 Validation Study

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Heart FailureHigh Blood PressureHigh CholesterolAnemiaDiabetesThyroid DiseasesKidney DiseasesClotting DisorderTraumaOther Disease
Interventions
DIAGNOSTIC_TEST

BVA-200

Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.

Trial Locations (1)

37830

Daxor Corporation, Oak Ridge

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Stern Cardiovascular Foundation, Inc.

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

Daxor Corporation

INDUSTRY